CN111751556A - C3抗体在制备检测试剂盒中的用途 - Google Patents
C3抗体在制备检测试剂盒中的用途 Download PDFInfo
- Publication number
- CN111751556A CN111751556A CN202010646866.5A CN202010646866A CN111751556A CN 111751556 A CN111751556 A CN 111751556A CN 202010646866 A CN202010646866 A CN 202010646866A CN 111751556 A CN111751556 A CN 111751556A
- Authority
- CN
- China
- Prior art keywords
- cancer
- antibody
- positive
- cerebral
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 14
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 14
- 206010008088 Cerebral artery embolism Diseases 0.000 claims abstract description 13
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims abstract description 13
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000010849 intracranial embolism Diseases 0.000 claims abstract description 13
- 206010008132 Cerebral thrombosis Diseases 0.000 claims abstract description 12
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 238000004879 turbidimetry Methods 0.000 claims abstract description 10
- 230000009385 viral infection Effects 0.000 claims abstract description 10
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 8
- 208000036142 Viral infection Diseases 0.000 claims abstract description 6
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 6
- 239000011886 peripheral blood Substances 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 5
- 230000002093 peripheral effect Effects 0.000 claims abstract description 5
- 238000002965 ELISA Methods 0.000 claims abstract description 3
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 3
- 238000005325 percolation Methods 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 12
- 239000004033 plastic Substances 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 9
- 239000000020 Nitrocellulose Substances 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 229920001220 nitrocellulos Polymers 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 241000283707 Capra Species 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 201000002510 thyroid cancer Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 206010046766 uterine cancer Diseases 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 6
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 239000013558 reference substance Substances 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 238000009739 binding Methods 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000003759 clinical diagnosis Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000012466 permeate Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010048620 Intracardiac thrombus Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100346189 Caenorhabditis elegans mpc-1 gene Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 201000008560 complement component 3 deficiency Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明属于生物工程领域,提供了C3抗体在制备检测外周血清、全血或末梢血用于诊断心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染或者病毒感染或者肿瘤的试剂盒中的用途。本发明将C3单克隆抗体或C3单克隆抗体和多克隆抗体包被,胶体金结合多克隆抗体,可提高试剂盒的灵敏度,也可和多克隆抗体联合使用,应用在免疫比浊法(免疫透射比浊法、免疫散射比浊法、免疫胶乳比浊法)、ELISA法、化学发光法、微流控芯片法、胶体金渗滤法及层析法上。本发明还提供了一种试剂盒,采用C3抗原‑抗体(包含有单克隆抗体和多克隆抗体)结合反应的方法进行检测,可应用于心或脑血栓心或脑梗脑溢血心或脑栓塞、细菌感染或者病毒感染和肿瘤的诊断。
Description
技术领域
本发明属于生物工程领域,涉及一种试剂盒,特别是采用C3在制备检测外周血清、全血或末梢血用于诊断心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染、病毒感染和肿瘤的试剂盒中的用途。
背景技术
C3:分子量185,000道尔顿.骨髓、脾、淋巴结、肝、肺、肠及各种巨噬细胞都有合成C3的功能。由于C3是经典活化途径和旁路活化途径的汇集点,因此C3的测定在临床得到广泛应用。遗传性C3缺陷在慢性肾炎、感染并发肾小球肾炎或心内膜炎、全身性红斑狼疮、急性、慢性肝炎、类风湿关节炎、血清病时血清C3水平下降;在多发性骨髓瘤、前列腺癌、移植排异反应时血清C3水平上升。
C3试剂盒原来是用于诊断外周血C3减少引发的疾病,在筛选上百种抗体中偶然发现在心或脑血栓、心或脑梗、脑溢血、心或脑栓塞诊断有关联,还与革兰氏阳性菌和革兰氏阴性菌、病毒感染指标和肿瘤如甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结·直肠癌、肾癌、胰腺癌、膀胱癌的诊断指标有关联。
发明内容
本发明的目的在于提供C3在制备检测外周血清、全血或末梢血用于诊断心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染或者病毒感染或者肿瘤的试剂盒中的用途,所述的这种用途要解决现有技术中检测心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染和肿瘤如甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结肠癌、直肠癌、肾癌、胰腺癌、膀胱癌的诊断或者病毒感染的手段有限、而且时间长的技术问题。
本发明提供了C3抗体在制备检测外周血清、全血或末梢血用于诊断心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染或者病毒感染和肿瘤的试剂盒中的用途。
进一步的,所述的肿瘤为甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结肠癌、直肠癌、肾癌、胰腺癌或者膀胱癌。
进一步的,所述的试剂盒包括检测板、兔抗C3抗体、由胶体金标记的羊抗C3抗体结合物、封闭液、洗涤液、阳性参考品,所述的检测板由一个塑料盒底盒组成,所述的塑料盒底盒中设置有一层吸水层,所述的吸水层上设置有一层硝酸纤维素膜,所述的硝酸纤维素膜上面覆盖一层滤网,所述的滤网上设置有一个塑料盒面盖,所述的塑料盒面盖中央设置有一个检测反应孔,在检测反应孔对应的硝酸纤维素膜上点加兔抗C3抗体和胶体金标记的羊抗C3抗体结合物,所述的封闭液是含有牛血清白蛋白的磷酸盐溶液,磷酸盐溶液的pH7.0~7.5之间,牛血清白蛋白在磷酸盐溶液中的重量百分比为1.0%,所述的洗涤液是含有Tween-20的Tris-HCl溶液,Tris-HCl溶液的pH在7.0~7.5之间,Tween-20在Tris-HCl溶液中的重量百分比为0.05%,在每毫升胶体金结合物中,羊抗C3抗体的质量为0.25克,所述的阳性参考品为浓度大于1.60g/L的C3抗原。
进一步的,采用胶体金渗滤法及层析法、化学发光法、进行检验。
进一步的,采用ELISA法、免疫比浊法、免疫透射比浊法、免疫散射比浊法或者免疫胶乳增强比浊法进行临床检验常规检测。
进一步的,采用微流控芯片进行检测。
进一步的,所述的兔抗C3抗体为单克隆抗体或者多克隆抗体。
本发明提供了一种试剂盒,采用C3抗原-抗体结合反应的方法进行检测。
进一步的,兔抗C3抗体为单克隆抗体或者多克隆抗体,提高试剂的灵敏度和准确性,(包含有鼠、兔、羊或者马的单克隆抗体或者多克隆抗体)。
本发明的检测原理是:C3抗体和血清中C3抗原的相结合反应。
本发明和已有技术相比,其技术进步是显著的。本发明可以用于检测人血清样本中C3抗原,作为心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染或者病毒感染和肿瘤如甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结·直肠癌、肾癌、胰腺癌、膀胱癌的诊断。采用本发明的试剂盒1分钟至5分钟内能收到检测报告,检测结果准确而且方便。
具体实施方式
实施例1.试剂盒的制备方法
1.1胶体金结合物制备工艺;
1.1.1制备胶体金;
1.1.1.1 0.05%氯化金溶液300毫升,加热至沸;
1.1.1.2加入5.0%柠檬酸三钠3.6毫升;
1.1.1.3继续加热煮沸15分钟,停止加热,待冷至室温,用蒸馏水恢复至原体积;
1.1.2胶体金标记;
1.1.2.1胶体金100mL;
1.1.2.2加1.0%无水碳酸钠溶液2.4毫升,校pH值6.4~7.2;
1.1.2.3加羊抗C3抗体(1.0mg/mL)2.5毫升,室温静止30分钟;
1.1.2.4搅拌加入10X Tris-HCl 20毫升调控pH 7.2~7.5;
1.1.2.5搅拌加入BSA:2克、PEG20000:1克、ProClin-300:0.2毫升;
1.2检测板制备工艺;
1.2.1装配检测板,取塑料盒底盖,放置吸水层,在吸水层上放置硝酸纤维素膜,盖上塑料盒面盖,压紧;
1.2.2检测点抗体:兔抗C3抗体(1.0mg/mL)1.0毫升加入1.0M NaHCO3:0.1毫升,混匀;
1.2.3取检测点抗体2.0uL,点加在检测板反应孔中心的硝酸纤维素膜上制成检测板;
1.3配制封闭液及洗涤液;
1.3.1配制封闭液,1.0%牛血清白蛋白,0.02M pH7.0~7.5磷酸盐溶液;
1.3.2配制洗涤液,0.05%Tween-20,0.05M pH7.0~7.5Tris-HCl溶液;
1.4正常参考范围确定,以C3抗原测定试剂盒的正常参考范围C3抗原含量0.80g/L—1.60g/L为依据,由于本法为定性检测,样品C3抗原含量在正常参考范围内检测点不显色,故选择以C3抗原含量约1.60g/L的样品做灵敏度检测;
1.4.1实验方法:
1、使用前先将试剂和样品取出,在室温中放置15~30分钟,使其恢复至室温;
2、取出检测板;
3、在检测板反应孔中心加入封闭液2滴,待封闭液完全渗入;
4、用移液器在检测板反应孔中心加入待测样品40微升,待样品完全渗入;
5、在检测板反应孔中心加入洗涤液4滴,待洗涤液完全渗入;
6、在检测板反应孔中心加入胶体金结合物3滴,待胶体金结合物完全渗入;
7、在检测板反应孔中心加入洗涤液4滴,待洗涤液完全渗入,目测结果;
【检验结果判读】
使用者在进行样品检测时,可能会出现如下情况:
a.检测板反应孔中心检测点有红色斑点,为阳性结果;
b.检测板反应孔中心检测点无红色斑点,为阴性结果。
【参考值(参考范围)】
以C3抗原测定试剂盒的正常参考范围C3抗原含量0.80g/L—1.60g/L为依据,样品C3抗原含量在正常参考范围内检测板反应孔中心检测点无红色斑点,
显示阴性结果;
正常参考范围:显示阴性结果(提示C3抗原含量0.80g/L—1.60g/L之间)。
【检验结果的解释】
1、阴性结果,则提示该样本的C3抗原含量0.80g/L—1.60g/L是正常范围;
2、阳性结果,则提示该样本的C3抗原含量>1.60g/L是不正常范围。
【检验方法的局限性】
1、本方法只能定性测定人血清样本中C3,仅作为辅助诊断使用;
2、反应斑点的稳定性:在30分钟内阳性斑点不会褪色,阴性结果仍无变化。
20例检测结果:(心或脑血栓、心或脑梗、脑溢血、心或脑栓塞病人)
阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
20例健康人(肝功能、肾功能、HBsAg、HIV、丙肝等皆为阴性)以0.80g/L—1.60g/L之间为阴性。
20例心或脑血栓、心或脑梗、脑溢血、心或脑栓塞4种病人和20例健康人结果对照,完全符合临床诊断。
10种肿瘤病人的60例结果:(甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结·直肠癌、肾癌、胰腺癌、膀胱癌)
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 | 阳性 |
实施例2:免疫胶乳比浊法试剂盒
仪器:7100生化仪
操作方法:将样本采用日立7100生化分析仪进行测定。在所述的一个将样本采用生化分析仪测定的步骤中,将样品加入试剂ⅠR1后,37℃孵育5min,读测第1点样本A1,加入试剂ⅡR2,37℃孵育5min,读测第2点样本A2,样本A=样本A2-样本A1;还包括一个将校准品采用日立7100生化分析仪测定的步骤,在所述的一个将校准品采用生化分析仪测定的步骤中,将校准品加入试剂ⅠR1后,37℃孵育5min,读测第1点校准A1,加入试剂ⅡR2,37℃孵育5min,读测第2点校准A2,校准A=校准A2-校准A1;
上述测定的参数为:温度37℃,波长600nm,R1:160uL R2:40uL。样本或校准品3μl,R1:240μl,R2:60μl,反应时间为10分钟。
测20例正常人(肝功能、肾功能、HBsAg、HIV、丙肝等皆为阴性)
0.92g/L | 1.27g/L | 1.55g/L | 0.99g/L | 1.41g/L |
0.97g/L | 1.22g/L | 1.46g/L | 0.86g/L | 1.57g/L |
0.83g/L | 1.45g/L | 1.30g/L | 1.59g/L | 1.53g/L |
1.13g/L | 1.53g/L | 1.28g/L | 1.34g/L | 1.43g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例健康人临床诊断结果在0.80g/L—1.60g/L之间,为阴性,符合临床诊断标准。
检测60例肿瘤患者(甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结·直肠癌、肾癌、胰腺癌、膀胱癌)
浓度在0.80g/L—1.60g/L之间是正常。
60例临床诊断结果在0.80g/L以下或1.60g/L以上,为阳性,符合临床诊断标准。
实施例3:20例脑溢血的标本(免疫比浊法)
仪器:7100生化仪
操作方法同实施例2
试剂盒参数:波长600nm,R1:160uL R2:40uL。
20例检测结果:
2.30g/L | 1.83g/L | 5.03g/L | 2.67g/L | 4.65g/L |
1.78g/L | 1.77g/L | 4.85g/L | 2.82g/L | 5.49g/L |
3.25g/L | 2.05g/L | 4.62g/L | 2.71g/L | 6.28g/L |
7.26g/L | 2.74g/L | 1.98g/L | 4.33g/L | 5.37g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例脑溢血病人临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
实施例4:20例心或脑梗塞的标本(免疫比浊法)
仪器:7100生化仪
操作方法同实施例2
参数:波长340nm,R1:160uL R2:40uL。
20例检测结果
3.35g/L | 2.53g/L | 2.75g/L | 4.65g/L | 3.12g/L |
3.46g/L | 5.70g/L | 7.92g/L | 6.58g/L | 3.42g/L |
4.98g/L | 2.34g/L | 2.65g/L | 2.83g/L | 2.64g/L |
1.87g/L | 1.99g/L | 3.75g/L | 2.24g/L | 5.48g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例心或脑梗塞病人临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
实施例5:20例心或脑血栓的标本(免疫比浊法)
仪器:7100生化仪
操作方法同实施例2
参数:波长600nm,R1:160uL R2:40uL。
20例检测结果
2.15g/L | 4.65g/L | 4.31g/L | 2.45g/L | 7.26g/L |
3.47g/L | 5.02g/L | 4.33g/L | 2.36g/L | 4.55g/L |
3.26g/L | 5.34g/L | 2.51g/L | 3.41g/L | 6.50g/L |
3.45g/L | 5.67g/L | 5.32g/L | 6.98g/L | 2.79g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例心或脑血栓病人临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
实施例6:20例心或脑栓塞的标本(免疫比浊法)
仪器:7100生化仪
操作方法同实施例2
参数:波长600nm,R1:160uL R2:40uL。
20例检测结果:
5.50g/L | 6.36g/L | 8.46g/L | 5.18g/L | 5.40g/L |
6.63g/L | 6.78g/L | 5.39g/L | 6.48g/L | 6.75g/L |
6.06g/L | 7.02g/L | 5.50g/L | 6.23g/L | 5.28g/L |
8.77g/L | 7.35g/L | 5.45g/L | 5.90g/L | 5.14g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例心或脑栓塞病人临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
实施例7:20例化学发光法
本发明化学发光法检测方法,其中包括以下步骤:
1、仪器:MPC-1化学发光测定仪
2、将抗人C3抗体固定在固相表面,加入待测样品和标记的抗人C3抗体,温育,然后用洗涤液洗涤;同时设立C3标准品的对照;
3、加入化学发光底物工作液,放置一段时间;
4、测量发光值,得到待测样本的C3浓度值。
20例检测结果:20例心或脑梗塞病人
5.86g/L | 7.50g/L | 6.19g/L | 5.95g/L | 8.55g/L |
5.63g/L | 7.74g/L | 6.05g/L | 6.53g/L | 6.46g/L |
6.15g/L | 5.84g/L | 7.71g/L | 8.40g/L | 6.73g/L |
6.52g/L | 6.16g/L | 6.65g/L | 7.44g/L | 8.46g/L |
浓度在0.80g/L—1.60g/L之间是正常。
20例临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
实施例8:50例革兰氏阳性菌、革兰氏阴性菌和病毒感染的标本(化学发光法)50例检测结果
浓度在0.80g/L—1.60g/L之间是正常。
50例例革兰氏阳性菌、革兰氏阴性菌和病毒感染的病人临床诊断结果在1.60g/L以上,为阳性,符合临床诊断标准。
本发明的上述实施例仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (8)
1.C3抗体在制备检测外周血清、全血或末梢血用于诊断心或脑血栓、心或脑梗、脑溢血、心或脑栓塞、细菌感染或者病毒感染和肿瘤的试剂盒中的用途。
2.根据权利要求1所述的用途,其特征在于:所述的肿瘤为甲状腺癌、肝癌、胃癌、子宫癌、宫颈癌、肺癌、乳腺癌、食道癌、鼻咽癌、前列腺癌、结肠癌、直肠癌、肾癌、胰腺癌或者膀胱癌。
3.根据权利要求1所述的用途,其特征在于:所述的试剂盒包括检测板、兔抗C3抗体、由胶体金标记的羊抗C3抗体结合物、封闭液、洗涤液、阳性参考品,所述的检测板由一个塑料盒底盒组成,所述的塑料盒底盒中设置有一层吸水层,所述的吸水层上设置有一层硝酸纤维素膜,所述的硝酸纤维素膜上面覆盖一层滤网,所述的滤网上设置有一个塑料盒面盖,所述的塑料盒面盖中央设置有一个检测反应孔,在检测反应孔对应的硝酸纤维素膜上点加兔抗C3抗体和胶体金标记的羊抗C3抗体结合物,所述的封闭液是含有牛血清白蛋白的磷酸盐溶液,磷酸盐溶液的pH7.0~7.5 之间,牛血清白蛋白在磷酸盐溶液中的重量百分比为1.0%,所述的洗涤液是含有Tween-20 的Tris-HCl 溶液,Tris-HCl 溶液的pH 在7.0~7.5之间,Tween-20 在Tris-HCl 溶液中的重量百分比为0.05%,在每毫升胶体金结合物中,羊抗C3抗体的质量为0.25 克,所述的阳性参考品为浓度大于1.60 g/L 的C3抗原。
4.根据权利要求1所述的用途,其特征在于:采用胶体金渗滤法及层析法、化学发光法、进行检验。
5.根据权利要求1所述的用途,其特征在于:采用ELISA法、免疫比浊法、免疫透射比浊法、免疫散射比浊法或者免疫胶乳增强比浊法进行临床检验常规检测。
6.根据权利要求1所述的用途,其特征在于:采用微流控芯片进行检测。
7.根据权利要求1所述的用途,其特征在于:所述的兔抗C3抗体为单克隆抗体或者多克隆抗体。
8.一种试剂盒,其特征在于:采用C3抗原-抗体结合反应的方法进行检测。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010646866.5A CN111751556A (zh) | 2020-07-07 | 2020-07-07 | C3抗体在制备检测试剂盒中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010646866.5A CN111751556A (zh) | 2020-07-07 | 2020-07-07 | C3抗体在制备检测试剂盒中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111751556A true CN111751556A (zh) | 2020-10-09 |
Family
ID=72679941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010646866.5A Pending CN111751556A (zh) | 2020-07-07 | 2020-07-07 | C3抗体在制备检测试剂盒中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111751556A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101718780A (zh) * | 2009-10-29 | 2010-06-02 | 广西师范大学 | 检测人血清补体3的免疫金同步散射光谱试剂盒及使用方法 |
US20150111776A1 (en) * | 2013-09-23 | 2015-04-23 | Assaypro, Llc | Immunoassays using over-labeled fluorescent probes |
CN107607724A (zh) * | 2017-08-11 | 2018-01-19 | 中山市创艺生化工程有限公司 | 一种用于补体c3测定试剂盒的复合稳定剂及其应用 |
-
2020
- 2020-07-07 CN CN202010646866.5A patent/CN111751556A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101718780A (zh) * | 2009-10-29 | 2010-06-02 | 广西师范大学 | 检测人血清补体3的免疫金同步散射光谱试剂盒及使用方法 |
US20150111776A1 (en) * | 2013-09-23 | 2015-04-23 | Assaypro, Llc | Immunoassays using over-labeled fluorescent probes |
CN107607724A (zh) * | 2017-08-11 | 2018-01-19 | 中山市创艺生化工程有限公司 | 一种用于补体c3测定试剂盒的复合稳定剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102266095B1 (ko) | 혈청 중의 비정상적인 디카르복실라제 프로트롬빈을 검출하기 위한 단백질 칩, 키트 및 그 제조방법 | |
CN110275028B (zh) | 一种胶体金标记的抗he4抗体试剂盒及其制备方法 | |
US20220057393A1 (en) | Methods for reducing interferences | |
CN112858675B (zh) | 一种新型冠状病毒抗原、抗体联合智能化检测装置 | |
JP2015508892A (ja) | 慢性b型肝炎患者の応答予測及び治療観察のためのb型肝炎ウイルス免疫複合体 | |
CN111751556A (zh) | C3抗体在制备检测试剂盒中的用途 | |
CN110412274B (zh) | C6orf106自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
CN111693699A (zh) | C4抗体在制备检测试剂盒中的用途 | |
CN111693697A (zh) | C3c抗体在制备检测试剂盒中的用途 | |
CN111693700A (zh) | B因子抗体在准备检测试剂盒中的用途 | |
EP2009444B1 (en) | Non-invasive test method for non-alcoholic steatohepatitis based on cytochrome-c quantification | |
CN109187943B (zh) | 一种抗干扰试剂杯以及试剂杯内抗干扰涂层的制备方法 | |
CN110596389B (zh) | Esrp1自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
CN111562374A (zh) | 葡萄糖6磷酸异构酶试剂盒的新用途 | |
CN111751555A (zh) | H因子抗体在制备检测试剂盒中的用途 | |
CN111693698A (zh) | 补体C1q抗体在制备检测试剂盒中的用途 | |
US20210389326A1 (en) | Method for detecting viral liver cancer | |
CN111638368A (zh) | 一种用于早期筛查诊断的试剂盒 | |
CN114487410A (zh) | H因子抗体在制备检测血液透析、腹膜透析、腹膜炎或者胶质瘤的试剂盒中的用途 | |
JPS6091264A (ja) | フイブロネクチンの免疫学的測定 | |
CN110632312B (zh) | A1cf自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 | |
CN115950868B (zh) | 一种抗体-斑点法进行糖化白蛋白测定的测试装置及其测试方法 | |
EP4075136A1 (en) | Rapid detection kit for anti-tnf-alpha drug monitoring | |
CN220137151U (zh) | 一种检测2型糖尿病并发结直肠癌的试剂盒 | |
CN110632308B (zh) | Casp8自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201009 |
|
WD01 | Invention patent application deemed withdrawn after publication |